Periostin as a novel biomarker of cardiovascular disease: A systematic evidence landscape of preclinical and clinical studies

Abstract

Background Periostin is a matricellular protein, expressed in various normal adult and fetal tissues. Recently, elevated periostin levels have been reported in heart failure, coronary artery disease, and stroke. However, there is lack of clinical studies to clarify the prognostic significance of systemic periostin levels in cardiovascular diseases (CVDs). The aim of the study was to perform a systematic review of published evidence on periostin and CVDs, and to clarify the diagnostic and prognostic significance of systemic periostin levels in CVDs. Methods A systematic search on PubMed was performed to identify relevant articles from inception to December 2018. The eligible studies evaluating the periostin expression and periostin levels in animal and human studies. Results A total of 24 relevant studies, including both animal and human data, were included. Periostin is significantly observed in myocardium tissue of failing hearts compared with control, and is also expressed in atherosclerotic plaques. Systemic periostin levels were significantly correlated with cardiac function and severity of CVD in several studies. A clinical study also observed positive correlation between periostin and N‐terminal pro b‐type natriuretic peptide (NT‐proBNP), highly sensitive troponin (hsTnT), and ST2 cardiac biomarker. Studies reported limited adjustment for potential confounders. Conclusions The evidence of current review support potential role of periostin in the pathophysiology of CVD. However, scarcity of data regarding the clinical use of periostin levels in the current management of CVDs further creates room for the future investigation. Therefore, further studies warrant to clarify its potential role, if any, as a novel cardiac biomarker.

Is There a Link between COVID-19 Infection, Periodontal Disease and Acute Myocardial Infarction?

“…Furthermore, in a study conducted by Chen et al (2017), it was shown that in neonatal mice, the Pn level was significantly increased at 1, 3 and 7 days after an ACS (p < 0.01) [39]. Recent data also proved that Pn is involved in the atherosclerosis process and its serum level is increased in advanced forms of heart failure or ACS [40].…”

Different Lipid Parameters in Predicting Clinical Outcomes in Chinese Statin-Naïve Patients After Coronary Stent Implantation

“…Post-percutaneous coronary intervention (PCI) patients represent a special CVD population (2), as they require secondary prevention for coronary heart disease (3). Predicting further CVD risk in such populations is critically relevant for clinical decision making, and novel factors that are potentially associated with CVD risk are being investigated (4). Lipid profiles are the most critical factors for CVD prevention, and low-density lipoprotein cholesterol (LDL-C) is a key risk factor for CVD (5,6).…”

Predictor for cardiovascular risk in patients with type-2 diabetes mellitus

“…9 Altered and overexpression of periostin was found in wide variety of diseases including cancer, lung disease, and CVD. 8,10 Periostin may critically act as a scaffold and remodeling protein in inflammatory responses, obesity, and insulin resistance, that may reflect a novel molecular hint for the pathogenesis of T2DM and obesity. 11 As TG have risen as the favored storage supplement for buffering against variations in energy demand and accessibility, dysregulated TG collection is firmly related to chronic inflammation, obesity and metabolic disorder.…”